Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 18/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 18/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 18/20 | 0.60 |
| ▸ | CHRNB3 | Q05901 | 18/20 | 0.60 |
| ▸ | CHRNA6 | Q15825 | 18/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14211293 | 0.92 | CHRNB2 (0.56) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14211347 | 0.92 | CHRNB2 (0.56) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14211311 | 0.88 | CHRNB2 (0.51) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14211304 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1462662 | 0.76 | CHRNB2 (0.63) | CHRNB2CHRNA3CHRNA4NAMPT | |
| SCHEMBL1464607 | 0.76 | CHRNB2 (0.64) | CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL25307104 | 0.75 | KDM1A (0.45) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1978271 | 0.75 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL23019192 | 0.74 | NAMPT (0.45) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14211292 | 0.74 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8802694-B2 | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands | TARGACEPT, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802694-B2 | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands | TARGACEPT, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | TARGACEPT, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | TARGACEPT, INC. (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA3, CHRNA6 | CHRNB2 9/4885CHRNA3 2/4885CHRNA4 6/4885 |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | CHRNA3, CHRNA2, CHRNA6 | CHRNB2 9/4885CHRNA3 1/4885CHRNA4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.